ES2122041T3 - Glicosidos triantenarios aglomerados, su preparacion y utilizacion. - Google Patents

Glicosidos triantenarios aglomerados, su preparacion y utilizacion.

Info

Publication number
ES2122041T3
ES2122041T3 ES93921124T ES93921124T ES2122041T3 ES 2122041 T3 ES2122041 T3 ES 2122041T3 ES 93921124 T ES93921124 T ES 93921124T ES 93921124 T ES93921124 T ES 93921124T ES 2122041 T3 ES2122041 T3 ES 2122041T3
Authority
ES
Spain
Prior art keywords
pct
date
cluster
triantenary
glycosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921124T
Other languages
English (en)
Inventor
Ericus Anna Leonardus Biessen
Berkel Theodorus Josephus Van
Boom Jacobus Hubertus Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
Nederlandse Hartstichting
Original Assignee
Universiteit Leiden
Nederlandse Hartstichting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden, Nederlandse Hartstichting filed Critical Universiteit Leiden
Application granted granted Critical
Publication of ES2122041T3 publication Critical patent/ES2122041T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals

Abstract

SE PRESENTA UN GLICOSIDO DE AGRUPACION TRIANTENARIA, EN DONDE CADA RESIDUO DE GLICOSIDO ESTA UNIDO AL PUNTO DE RAMIFICACION DE LA AGRUPACION POR UN SEPARADOR DE CADENA LARGA, FLEXIBLE, HIDROFILICA QUE COMPRENDE AL MENOS CUATRO ATOMOS EN LA CADENA. EL SEPARADOR DE GLICOSIDO COMPRENDE PREFERIBLEMENTE AL MENOS DOS GRUPOS HIDROFILICOS. TAMBIEN SE PRESENTA EL USO DEL GLICOSIDO DE AGRUPACION TRIANTENARIA EN PREPARACIONES FARMACEUTICAS, POR EJEMPLO COMO MEDICAMENTOS HIPOLIPIDEMICOS.
ES93921124T 1992-08-11 1993-08-11 Glicosidos triantenarios aglomerados, su preparacion y utilizacion. Expired - Lifetime ES2122041T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.

Publications (1)

Publication Number Publication Date
ES2122041T3 true ES2122041T3 (es) 1998-12-16

Family

ID=19861173

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921124T Expired - Lifetime ES2122041T3 (es) 1992-08-11 1993-08-11 Glicosidos triantenarios aglomerados, su preparacion y utilizacion.

Country Status (10)

Country Link
US (1) US5885968A (es)
EP (1) EP0655070B1 (es)
JP (1) JPH08502726A (es)
AT (1) ATE168694T1 (es)
AU (1) AU674160B2 (es)
DE (1) DE69319912T2 (es)
DK (1) DK0655070T3 (es)
ES (1) ES2122041T3 (es)
NL (1) NL9201440A (es)
WO (1) WO1994004545A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030386A1 (fr) * 1995-03-31 1996-10-03 Drug Delivery System Institute, Ltd. Derives d'amidite et derives d'oligonucleotides
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19631189A1 (de) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
GB2372502B (en) * 2000-12-12 2004-10-13 Imperial College Carbohydrate compounds containing cholesterol and their use
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
MX2012009178A (es) 2010-02-24 2012-11-30 Arrowhead Res Corp Composiciones para liberacion dirigida de arnsi.
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
KR20130132475A (ko) 2010-12-17 2013-12-04 애로우헤드 리서치 코오포레이션 ｓｉＲＮＡ의 갈락토오스 클러스터-약동학적 조절제 표적 물질
WO2013032829A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US20140100178A1 (en) * 2012-10-04 2014-04-10 Aslam Ansari Composition and methods for site-specific drug delivery to treat malaria and other liver diseases
MY173826A (en) 2012-11-15 2020-02-24 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
BR112015018161A2 (pt) 2013-01-30 2017-08-22 Hoffmann La Roche Conjugado de oligômeros antisense de lna, composição farmacêutica e uso de um conjugado de oligômeros antisense de lna
CN112263682A (zh) 2013-06-27 2021-01-26 罗氏创新中心哥本哈根有限公司 靶向pcsk9的反义寡聚体和缀合物
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
MX2017011422A (es) 2015-03-17 2017-11-10 Arrowhead Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen del factor xii.
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN113797348A (zh) 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体
AU2017235278C1 (en) 2016-03-14 2022-03-10 F. Hoffmann-La Roche Ag Oligonucleotides for reduction of PD-L1 expression
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
EP3506913A4 (en) * 2016-09-02 2020-06-10 Arrowhead Pharmaceuticals, Inc. TARGETING LIGANDS
WO2018132432A1 (en) 2017-01-10 2018-07-19 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use
EP3385272A1 (en) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Further novel oligonucleotide-ligand conjugates
EP3550022A1 (en) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Products and compositions
EP3385381A1 (en) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Products and compositions
PL3607068T3 (pl) 2017-04-05 2023-03-20 Silence Therapeutics Gmbh Hamowanie TMPRSS6 mediowane interferencją RNA
WO2018185253A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Ligand modified double-stranded nucleic acids
EP3385380A1 (en) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Products and compositions
EP3483269A1 (en) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
WO2018185252A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Nucleic acid conjugates
RS63836B1 (sr) 2017-04-05 2023-01-31 Silence Therapeutics Gmbh Proizvodi i sastavi
EP4029942A1 (en) 2017-04-05 2022-07-20 Silence Therapeutics GmbH Products and compositions
SG11201912178VA (en) 2017-09-11 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
CN117701562A (zh) 2017-09-14 2024-03-15 箭头药业股份有限公司 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法
CN111511914B (zh) 2017-10-16 2023-11-17 豪夫迈·罗氏有限公司 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
US11492624B2 (en) 2017-10-17 2022-11-08 Arrowheads Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
EP3483270A1 (en) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
LT3710586T (lt) 2017-11-13 2023-02-27 Silence Therapeutics Gmbh Nukleorūgštis, skirta slopinti lpa raišką ląstelėje
JP7461886B2 (ja) 2017-11-13 2024-04-04 サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 標的遺伝子の発現を抑制するためのジチオリン酸結合を含む核酸
WO2019092282A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
EP3550021A1 (en) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Products and compositions for inhibiting expression of a target gene
EP3775207A1 (en) 2018-04-05 2021-02-17 Silence Therapeutics GmbH Sirnas with vinylphosphonate at the 5' end of the antisense strand
CR20210058A (es) 2018-07-03 2021-03-22 Hoffmann La Roche Oligonucleótidos para modular la expresión de tau
EP3598995A1 (en) 2018-07-26 2020-01-29 Silence Therapeutics GmbH Products and compositions
CN113728102A (zh) 2018-08-28 2021-11-30 罗氏创新中心哥本哈根有限公司 使用剪接调节化合物进行新抗原工程化
JP7245328B2 (ja) 2018-11-13 2023-03-23 サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞におけるｌｐａの発現を抑制するための核酸
EP3730617A1 (en) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of c3 in a cell
CA3119234A1 (en) 2018-11-23 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
WO2020163747A1 (en) 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for hepatitis b virus infection
EP3931348B1 (en) 2019-02-26 2023-08-09 Roche Innovation Center Copenhagen A/S Oligonucleotide formulation method
CA3135958A1 (en) 2019-05-07 2020-11-12 Universitat Bern Nucleic acids for inhibiting expression of pros1 in a cell
CN114340664A (zh) 2019-06-18 2022-04-12 爱尔兰詹森科学公司 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
CN114981430A (zh) 2019-08-27 2022-08-30 赛伦斯治疗有限责任公司 用于抑制细胞中的c3表达的核酸
JP2023509872A (ja) 2019-12-24 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー Ｈｂｖを標的とする抗ウイルス剤及び／又はｈｂｖの処置のための免疫調節剤の医薬組合せ
MX2022007908A (es) 2019-12-24 2022-07-21 Hoffmann La Roche Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
US20210301294A1 (en) 2020-03-26 2021-09-30 Arrowhead Pharmaceuticals, Inc. RNAi Agents For Inhibiting Expression Of PNPLA3, Pharmaceutical Compositions Thereof, And Methods Of Use
AU2021281511A1 (en) 2020-05-27 2023-01-05 Asociación Centro de Investigación Cooperativa en Biociencias- CIC bioGUNE Nucleic acids for inhibiting expression of CNNM4 in a cell
AU2021345026A1 (en) 2020-09-15 2023-05-11 Arrowhead Pharmaceuticals, Inc. Methods for the reduction of z-aat protein levels
WO2022096424A1 (en) 2020-11-04 2022-05-12 Universität Bern Nucleic acids for inhibiting expression of pros1 in a cell
WO2022184852A1 (en) 2021-03-03 2022-09-09 Silence Therapeutics Gmbh Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
WO2022223557A1 (en) 2021-04-20 2022-10-27 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of xdh in a cell
EP4329876A1 (en) 2021-04-27 2024-03-06 Silence Therapeutics GmbH Sirna targeting tmprss6 for the treatment of myeloproliferative disorders
US11629349B2 (en) 2021-06-21 2023-04-18 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
AU2022336157A1 (en) 2021-09-02 2024-03-14 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US751219A (en) * 1904-02-02 Leaf-turner
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
FR2637185A1 (fr) * 1988-10-05 1990-04-06 Ire Celltarg Sa Vecteurs synthetiques de faible poids moleculaire, utilisation en therapie ciblee et en imagerie medicale et procedes de preparation
PT649854E (pt) * 1993-09-01 2000-07-31 Akzo Nobel Nv Bisconjugados compreendendo dois sacaridos e um espacador

Also Published As

Publication number Publication date
NL9201440A (nl) 1994-03-01
EP0655070B1 (en) 1998-07-22
US5885968A (en) 1999-03-23
ATE168694T1 (de) 1998-08-15
DK0655070T3 (da) 1999-04-26
WO1994004545A1 (en) 1994-03-03
EP0655070A1 (en) 1995-05-31
AU674160B2 (en) 1996-12-12
AU4835593A (en) 1994-03-15
DE69319912D1 (de) 1998-08-27
DE69319912T2 (de) 1999-04-15
JPH08502726A (ja) 1996-03-26

Similar Documents

Publication Publication Date Title
ES2122041T3 (es) Glicosidos triantenarios aglomerados, su preparacion y utilizacion.
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
SE8504945D0 (sv) Pharmaceutical compositions containing anthracycline glycosides
DK1042340T3 (da) 6-O-alkylerythromycinoxim-B
DZ2028A1 (fr) Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
DK160429C (da) N-heterocyclisk glycosid med antitumorvirkning, fremstilling deraf samt farmaceutisk praeparat indeholdende glycosidet
SE8702188L (sv) Farmaceutiska kompositioner
YU166790A (sh) Kompleksi koji imaju pomoćnu aktivnost
FI961054A0 (fi) Menetelmä 9-(2-hydroksi)etoksimetyyliguaniinin valmistamiseksi
ES2110084T3 (es) Sistema de canales con una seccion transversal de esquinas redondeadas.
NO920143L (no) Substituerte 2-imidazoliner og fremstilling og anvendelsederav
BR9913107A (pt) Derivados de benzoilguanidina, com propriedades vantajosas, processos para sua preparação e seu uso na produção de medicamentos
MX9302272A (es) Retinoides solubles en agua.
ES2174291T3 (es) Preparacion topica para introducir medicamentos peptidicos en organismos vivos.
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
MX9303985A (es) Nucleosidos terapeuticos.
ATE174509T1 (de) Metabolisierbarer plasmaersatz
Xu et al. Clinical trial of trichosanthin with or without dexamethasone in induction of abortion by four different routes of administration
DE69427966T2 (de) Neue o-sulfatierte ganglioside und lyso-ganglioside-derivaten
KR910009280A (ko) 원발성 흉막암 치료용 제약 조성물의 제조에 있어서 감마 인터페론 활성을 갖는 폴리펩티드의 용도
Sova et al. Natural inhibitors of carbohydrases.
ITMI911688A1 (it) Indipendenza alimentare per unita' civili e militari
IT1255678B (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.
RU2076528C1 (ru) Штамм вируса омской геморрагической лихорадки для приготовления диагностических препаратов

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19950505

FG2A Definitive protection

Ref document number: 655070

Country of ref document: ES